Repligen Management
Management criteria checks 2/4
Repligen's CEO is Olivier Loeillot, appointed in Oct 2023, has a tenure of 1.08 years. total yearly compensation is $5.45M, comprised of 2.5% salary and 97.5% bonuses, including company stock and options. directly owns 0.058% of the company’s shares, worth $4.64M. The average tenure of the management team and the board of directors is 1.8 years and 8.7 years respectively.
Key information
Olivier Loeillot
Chief executive officer
US$5.4m
Total compensation
| CEO salary percentage | 2.5% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.06% |
| Management average tenure | 1.8yrs |
| Board average tenure | 8.7yrs |
Recent management updates
Recent updates
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
Nov 12Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Nov 08
Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?
Oct 14Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price
Sep 08Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Jul 31We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt
Jul 15Repligen: Strong Filtration Growth, Offset By Other Challenges
Jul 13Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge
Jun 14Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?
Jun 10Repligen Stock: Still Quite Overvalued
May 30Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models
May 03Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$8m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | US$24m |
| Dec 31 2023 | US$5m | US$138k | US$36m |
Compensation vs Market: Olivier's total compensation ($USD5.45M) is below average for companies of similar size in the US market ($USD7.78M).
Compensation vs Earnings: Insufficient data to compare Olivier's compensation with company performance.
CEO
Olivier Loeillot (54 yo)
1.1yrs
Tenure
US$5,445,065
Compensation
Mr. Olivier Loeillot is President of Repligen Corporation from October 02, 2023 & served as it's Chief Commercial Officer and serves as it's CEO & Director since September 1, 2024. Mr. Loeillot served a co...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 9.5yrs | US$7.93m | 0.18% $ 14.5m | |
| President | 1.1yrs | US$5.45m | 0.058% $ 4.6m | |
| CFO & Chief Compliance Officer | 1.2yrs | US$2.03m | 0.014% $ 1.1m | |
| Chief Operating Officer | 4.7yrs | US$3.74m | 0.0075% $ 600.7k | |
| Senior Vice President of Research & Development | 8.1yrs | US$1.66m | 0.010% $ 819.6k | |
| Chief Information Officer | no data | no data | no data | |
| Global Head of Investor Relations | no data | no data | no data | |
| Global Head of Legal | no data | no data | no data | |
| VP & Global Head of Sales | 2.1yrs | no data | no data | |
| Senior Director of Marketing | less than a year | no data | no data | |
| Vice President of Human Resources | 1.8yrs | no data | no data | |
| Senior VP of Strategy and Business Development & Global Head of Bioprocess Analytics | 4.8yrs | no data | no data |
1.8yrs
Average Tenure
60yo
Average Age
Experienced Management: RGEN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | 9.5yrs | US$7.93m | 0.18% $ 14.5m | |
| President | less than a year | US$5.45m | 0.058% $ 4.6m | |
| Independent Director | 9.1yrs | US$322.84k | 0.056% $ 4.5m | |
| Member of Scientific Advisory Board | 8.7yrs | no data | no data | |
| Independent Director | 1.8yrs | US$453.50k | 0.0070% $ 559.2k | |
| Lead Independent Director | 19.2yrs | US$431.12k | 0.16% $ 12.9m | |
| Member of Scientific Advisory Board | 8.7yrs | no data | no data | |
| Member of Scientific Advisory Board & Independent Director | 8.7yrs | US$282.84k | 0.00095% $ 75.9k | |
| Member of Scientific Advisory Board | 8.7yrs | no data | no data | |
| Independent Director | 4.7yrs | US$287.84k | 0.0042% $ 334.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 10.4yrs | US$307.84k | 0.0071% $ 565.6k |
8.7yrs
Average Tenure
64yo
Average Age
Experienced Board: RGEN's board of directors are considered experienced (8.7 years average tenure).